Chemotherapy-enhanced angiogenesis is associated with an influx of BMDCs. (A) A schematic overview of the mouse model is shown. sc, subcutaneous. (B) The graph shows the tumor growth of LLC cells in C57BL/6 mice either untreated or treated with cisplatin or with paclitaxel. (C-D) The graphs show the percentage of PECAM⁺/CD45⁻ cells of the total cells in subcutaneous growing LLC cells in BL/6 mice transplanted with CIVE bone marrow, (C) 1 day or (D) 8 days after the start of treatment. (E-F) The graphs show the percentage of endothelial cells in subcutaneous growing C26 cells in BALB/c mice (E) 1 day or (F) 8 days after the start of treatment. (G-H) The graphs show the percentage of EYFP⁺ cells in LLC tumors in BL/6 mice transplanted with CIVE bone marrow (G) 1 or (H) 8 days after treatment. *P < .05; **P < .01; ***P < .001 compared with the vehicle control.